Despite a record-setting number of overdose deaths nationwide in 2022, a new study from Oregon Health & Science University finds that only one in four adolescent residential treatment centers nationwide provides buprenorphine, a proven medication to treat opioid use disorder. ‘It’s hard to imagine getting adolescents with opioid use disorder off fentanyl without buprenorphine,’ says co-author Todd Korthuis, M.D., M.P.H., head of addiction medicine at OHSU. (OHSU)
